Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Ralph
Psy167 - Comparison of Pharmacoeconomic (Pe) Evaluations for Drugs for Rare Diseases (Drds) Evaluated by Cadth and Nice.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Government Insists NHS Pays for Drugs Approved by NICE
BMJ
Pms83 - Comparison of French and German Hta Assessments for Three Recently Evaluated Rheumatoid Arthritis Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
New Drugs for Mental Diseases?: New Diseases for Old Drugs?
Journal of the Royal Society of Medicine
Medicine
The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases
Medical Decision Making
Health Policy
Comparison of Recent Hta Appraisals of Orphan Drugs by Nice, SMC and Has in 2015-2017
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PCN177 Assessment of Reimbursement Processes and Outcomes for Cancer Drugs in Croatia – Comparison to NICE and NCCN Guidelines
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Factors Associated With Positive and Negative Recommendations for Cancer and Non-Cancer Drugs for Rare Diseases in Canada
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PUK2 Issues in the Systematic Review of Drugs for Rare Diseases: A Case Study of Eculizumab for aHUS
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
